Industry News
Individualized cancer treatment targeting the tumor, not the whole body, a step closer
3/22/2016
They look like small, translucent gems but these tiny 'gel' slivers hold the world of a patient's tumour in microcosm ready for trials of anti-cancer drugs to find the best match between treatment...
ANGLE plc, the specialist medtech company, is delighted to announce that the results of Barts Cancer Institute's ongoing work with ANGLE's Parsortix system have provided evidence in support of the...
UCLA study uncovers key new insights into how cells are wired to survive radiation therapy
3/21/2016
Findings are a promising step toward more effective and tailored treatments for people with cancer.
'Silencer molecules' switch off cancer's ability to spread around body
3/21/2016
Scientists have revealed that a key molecule in breast and lung cancer cells can help switch off the cancers' ability to spread around the body.
Prostate cancer targeted with ultrasound 'could transform treatment'
3/21/2016
A new treatment for prostate cancer using focused ultrasound that appears as effective as surgery or radiotherapy - with fewer side effects - shows promising medium-term results.
NICE recommends abiraterone for prostate cancer
3/21/2016
NICE has issued final guidance recommending abiraterone (marketed as Zytiga by Janssen) for some prostate cancer patients*.
Moffitt pathologists identify new potential target in ovarian serous cancer
3/21/2016
A study presented at 2016 Annual USCAP Conference shows HER4 expression may be linked to chemotherapy resistance and a lower survival rate.
Saliva liquid biopsy for non small cell lung carcinoma (NSCLC) patients
3/21/2016
At the 45th Annual Meeting & Exhibition of the American Association for Dental Research, researcher David Wong, University of California - Los Angeles, USA, presented a study titled "Saliva Liquid...
USC researchers discover a key difference between mouse and human kidney cells
3/21/2016
The best laid plans of mice and men are a bit different -- at least when it comes to kidney development.
Cobimetinib in melanoma with BRAF V600 mutation: Indication of minor added benefit
3/21/2016
Negative effects resulted in a downgrading of the extent of the positive effects.